Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in lung cancer presented at ASCO 2014

Comment: Advances in breast cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC